Literature DB >> 7952628

Airway eosinophilia in chronic bronchitis during exacerbations.

M Saetta1, A Di Stefano, P Maestrelli, G Turato, M P Ruggieri, A Roggeri, P Calcagni, C E Mapp, A Ciaccia, L M Fabbri.   

Abstract

To examine the nature and the degree of airway inflammation in chronic bronchitis during exacerbations, bronchial biopsies and sputum were obtained in 11 subjects with chronic bronchitis examined during an exacerbation, and in 12 subjects with chronic bronchitis examined under baseline conditions. All subjects were nonatopic. Lobar bronchial biopsies were assessed using histochemical and immunohistochemical techniques, and sputum was examined for differential cell counts of leukocytes. Subjects with bronchitis during exacerbations had, on average, 30-fold more eosinophils in their bronchial biopsies than did those examined under baseline conditions (p < 0.001). Although to a lesser extent, the numbers of neutrophils (p < 0.01), T-lymphocytes (CD3) (p < 0.05), VLA-1-positive cells (p < 0.01), and TNF-alpha positive cells (p < 0.05) were also increased during exacerbations. By contrast, the T-lymphocyte subpopulations (CD4 and CD8) and the numbers of macrophages, mast cells, IL-2R-positive cells, and IL-1 beta-positive cells were similar in the two groups of subjects, as well as the percentages of ICAM-1- and E-selectin-positive vessels. Eosinophils were also increased in sputum of subjects with exacerbations when compared with those examined under baseline conditions (p < 0.05). In conclusion, exacerbations of chronic bronchitis are associated with a marked airway eosinophilia and with a milder increase in the number of neutrophils, activated T-lymphocytes, and TNF-alpha-positive cells in the bronchial mucosa.

Entities:  

Mesh:

Year:  1994        PMID: 7952628     DOI: 10.1164/ajrccm.150.6.7952628

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  105 in total

Review 1.  Home treatment of COPD exacerbations.

Authors:  D S Postma; N H Ten Hacken; H A Kerstjens; G H Koëter
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

Review 3.  Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease.

Authors:  J A Wedzicha
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

4.  Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy study.

Authors:  K Amin; A Ekberg-Jansson; C-G Löfdahl; P Venge
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

Review 5.  Management of an acute exacerbation of copd: are we ignoring the evidence?

Authors:  M K Johnson; R D Stevenson
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 6.  Acute effects of cigarette smoke on inflammation and oxidative stress: a review.

Authors:  H van der Vaart; D S Postma; W Timens; N H T ten Hacken
Journal:  Thorax       Date:  2004-08       Impact factor: 9.139

7.  Neutrophilic infiltration within the airway smooth muscle in patients with COPD.

Authors:  S Baraldo; G Turato; C Badin; E Bazzan; B Beghé; R Zuin; F Calabrese; G Casoni; P Maestrelli; A Papi; L M Fabbri; M Saetta
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

Review 8.  Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease.

Authors:  L Fabbri; B Beghé; G Caramori; A Papi; M Saetta
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

9.  Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.

Authors:  A Bhowmik; T A Seemungal; R J Sapsford; J A Wedzicha
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 10.  Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

Authors:  S F Paul Man; Don D Sin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.